tbuckley/cabot-search huggingface dataset:
The BAFF Inhibitor AMG523 Blocks Adhesion and Survival of Human Multiple Myeloma Cells in the Bone Marrow Microenvironment: Clinical Implication.
Authors: Yu-Tzu Tai, Jiangchun Xu, Xian-Feng Li, Iris Breitkreutz, Klaus Podar, Teru Hideshima, Robert Schlossman, Paul Richardson, Nikhil C. Munshi, Kenneth C. Anderson
Journal: Blood (2006)
The Mas-Related G Protein-Coupled Receptor MRGPRX2 Is Expressed on Human Basophils and up-Regulated upon Activation
Authors: Vito Sabato, Athina Van Gasse, Nathalie Cop, Karen Claesen, Ine I. Decuyper, Margaretha A. Faber, Chris Bridts, Christel Mertens, Margo Hagendorens, Luc De Clerck, Didier G. Ebo
Journal: Journal of Allergy and Clinical Immunology (2017)
451PD Osimertinibat 80mg for refractoryleptomeningeal metastases in T790M-positive EGFR-mutant non-small cell lung cancer
Authors: A. Hata, S. Nanjo, C. Okuda, R. Kaji, K. Masago, S. Fujita, K. Irie, H. Okada, H. Okada, H. Okada, S. Fukushima, N. Katakami
Journal: Annals of Oncology (2016)
How do hospital doctors manage patients with medically unexplained symptoms: a qualitative study of physicians
Authors: Alex Warner, Kate Walters, Kethakie Lamahewa, Marta Buszewicz
Journal: Journal of the Royal Society of Medicine (2017)

Objective Medically unexplained symptoms are a common presentation in medical practice and are associated with significant morbidity and high levels of service use. Most research exploring the attitudes and training of doctors in treating patients with unexplained symptoms has been conducted in primary care. This study aims to explore the ways in which doctors working in secondary care approach and manage patients with medically unexplained symptoms. Design A qualitative study using in-depth interviews and thematic analysis. Setting Three hospitals in the North Thames area. Participants Twenty consultant and training-grade physicians working in cardiology, gastroenterology, rheumatology and neurology. Main outcome measure Physicians' approach to patients with medically unexplained symptoms and their views on managing these patients. Results There was considerable variation in how the physicians approached patients who presented with medically unexplained symptoms. Investigations were often ordered without a clear rationale and the explanations given to patients when results of investigations were normal were highly variable, both within and across specialties. The doctor's level of experience appeared to be a more important factor in their investigation and management strategies than their medical specialty. Physicians reported little or no formal training in how to manage such presentations, with no apparent consistency in how they had developed their approach. Doctors described learning from their own experience and from senior role models. Organisational barriers were identified to the effective management of these patients, particularly in terms of continuity of care. Conclusions Given the importance of this topic, there is a need for serious consideration as to how the management of patients with medically unexplained symptoms is included in medical training and in the planning and delivery of services.
Once-Daily Oral Deferasirox (Exjade®, ICL670) Versus Infusional Deferoxamine as Iron Chelation Therapy in Patients with Sickle-Cell Disease Receiving Frequent Transfusions: A Cost-Effectiveness Analysis.
Authors: Thomas E. Delea, Simu K. Thomas, Jean-Francois Baladi, Thomas D. Coates
Journal: Blood (2005)
Hybrid-capture based sequencing assays to detect novel alterations in BRAF from tissue and liquid biopsies
Authors: J. Müller, S. Lakis, E. Mariotti, P. Schneider, C. Glöckner, F. Leenders, A. Hube, G. Gullo, J. Crown, F. Griesinger, J. Heuckmann, L. Heukamp, R. Menon
Journal: Annals of Oncology (2016)
Exploring factors influencing sexual satisfaction among breast cancer survivors: The role of sexual communication.
Authors: Catalina Rosario Lawsin, Angela Ballard
Journal: Journal of Clinical Oncology (2016)

251 Background: Changes to sexual wellbeing after cancer treatment can impact sexual satisfaction, depending on sexual function and relationship satisfaction. While communication has been shown to be a critical component of supportive relationships, it is unclear how it impacts sexual satisfaction, particularly amongst cancer survivors. This study aims to develop a model to understand factors of sexual satisfaction amongst breast cancer (BC) survivors and explore the role of communication. Methods: Adult (18+) BC survivors were invited to participate in an online survey via Register4. Measures included: demographics, the PROMIS Global Satisfaction with Sex Life Scale, Female Sexual Function Index, Sexual Self-Disclosure Questionnaire, The Dyadic Sexual Communication Scale, Dyadic Adjustment Scale, the Hospital Anxiety and Depression Scale. Research questions were addressed using correlations and a hierarchical Multiple Linear Regression. Results: 238 BC survivors (ave age=53) reported lower levels of sexual function within this sample when compared to other studies (FSFI M =17.96, SD =10.39). Higher levels of education (r=.17), dating or de facto relationships (r=.19) and living separately(r=.23), younger age (r=-.16) and shorter relationship length (r=-.14) were associated with higher levels of sexual satisfaction (p&lt;.01). Education level, sexual function and sexual communication explained 78.5% of the variance in sexual satisfaction. There was a significant interaction of sexual function and sexual communication where the effect of high levels of sexual communication was increased at high levels of sexual function compared to lower levels of sexual function (β=.101, p=.005). Conclusions: Sexual function and communication play a significant role in sexual satisfaction amongst BC survivors. While many strategies to improve sexual function may be handled by women themselves, others require effective sexual communication with their partners. These results highlight the need for interventions to teach patients effective sexual communication after sexual changes due to cancer treatment.
CARD: A randomized phase 4 trial comparing cabazitaxel and an androgen receptor (AR)-targeted agent in men with metastatic castration-resistant prostate cancer (mCRPC) progressing after docetaxel and an alternative AR-targeted agent
Authors: R. de Wit, K. Fizazi, E. Efstathiou, R. Dittamore, S. Hitier, K. Pantel, C. Sternberg, B. Tombal, C. Wülfing, J. de Bono
Journal: Annals of Oncology (2016)
Raised faecal calprotectin levels in pateints presenting with right iliac fossa pain warrant mandatory laparoscopy: A non-invasive predictor of acute appendicitis
Authors: C Power, H Al-Suwaidi, K Muhammad, M Floyd, M Kell, C Barry-Kinsella, P Keeling, TN Walsh
Journal: Endoscopy (2005)

Background: Despite advances in medical investigation the rates of negative appendicectomy remain unchanged. We investigated whether faecal calprotectin levels (FCP), a bowel lumen inflammatory marker, could accurately diagnose acute appendicitis.
Use of Multi Color P27kip1 Based Flow Cytometric Assay To Evaluate and Characterize G0 to G1 Cell Cycle Related Changes in Human Hematopoietic Cells after Subjection to a Clinically Applicable Ex Vivo Transduction Protocol.
Authors: Jesper Bonde, Phillip Herrbrich, Ryan Lahey, Jan A. Nolta
Journal: Blood (2004)
Human Metapneumovirus Small Hydrophobic Protein Inhibits Interferon Induction in Plasmacytoid Dendritic Cells via TLR7 Signaling Pathway
Authors: Anar Dossumbekova, Deepthi Kolli, Dana L. Esham, Tianshuang Liu, Antonella Casola
Journal: Journal of Allergy and Clinical Immunology (2017)
Efficacy and safety of sequential usage of everolimus in Asian patients with metastatic renal cell carcinoma (mRCC): Cooperative results from Osaka Urologic Oncology Group (OUOG).
Authors: Teruo Inamoto, Hirotsugu Uemura, Norio Nonomura, Tatsuya Nakatani, Tadashi Matsuda, Haruhito Azuma
Journal: Journal of Clinical Oncology (2012)

456 Background: Data on the efficacy and safety of everolimus (EVE) in Japanese patients (pts) are lacking because only 15 Japanese pts enrolled in the EVE group from the RECORD-1 global study. Efficacy and safety of sequential usage of EVE after other targeted therapies or immunotherapy in Japanese pts were examined. Methods: We retrospectively reviewed the records of consecutive pts with mRCC (median age 65, M:F 78/22, 78% clear cell) who received salvage EVE at 39 tertiary institutions in Osaka Urologic Oncology Group (OUOG) between 10/09-8/11. Data on safety (NCI-CTC) and efficacy (response assessment, progression-free survival [PFS]) were analyzed. 31% of pts had progressed on sunitinib, 22% on sorafenib, 1% on axitinib, 41% on sequential (sunitinib:sorafenib), and 5% no prior therapy. 50% received previous cytokines in addition to targeted therapies. Results: 172 pts with mRCC were enrolled. Median PFS was 2.8 months. Median time to last follow-up was 3.5 months (range 0.4-15.2 months). 44% continued EVE at last follow-up. 4.7% had partial response (PR) and 51.7% had stable disease (SD) by treating physician assessment. Of 112 pts who discontinued EVE, 46% discontinued EVE due to progressive disease (PD) (median time to PD 3.0 months, range 0.1-15.8 months), 43% discontinued due to adverse events (AEs) (median time to PD 1.5 months, range 0.1-12.6 months), and 0.6% died of PD on treatment. There were no treatment related deaths. The incidence of AEs of all grades was 88.4%. Major AEs were stomatitis (44.2%), thrombocytopenia (30.8%), and interstitial lung diseases (ILD) (22.1%). The incidence of AEs (Grades 3-4) was 52.9%. Serious AEs were anemia (7.6%), ILD (5.8%), and hyperglycemia (4.7%). Time to onset for these AEs was less than one month, showing marked contrast to that of ILD which ranged over several months. Conclusions: EVE demonstrated clinically relevant activity in Japanese patients with mRCC following PD with other targeted therapies or immunotherapy. Patients prone to serious AEs should be carefully observed for the occurrence of ILD throughout the treatment period.
78P Population based mammographic screening in India: Analysis from community outreach cancer screening program
Authors: S.S. Bisht, T. Kataria, D. Gupta, A. Abhishek, S. Goyal, T. Basu, K. Narang, M. Tayal, S. Banarjee, J. Arora, S. Razdan
Journal: Annals of Oncology (2016)
Developing infrastructure to improve research and care for cancer survivors: A pilot study.
Authors: Shoshana M. Rosenberg, Jennifer A. Ligibel, Jeffrey A. Meyerhardt, Eric D. Jacobsen, Judy Ellen Garber, Larissa Nekhlyudov, Craig A. Bunnell, Sarah Walsh, Ann H. Partridge
Journal: Journal of Clinical Oncology (2016)

61 Background: Despite a growing number of clinical trials and supportive care programs for cancer survivors, recruitment of patients (pts) for these opportunities during the survivorship phase of care is challenging. We piloted a program to systematically share available research studies and supportive care programs with pts as part of their treatment summary and survivorship care plan (TS/SCP) visit at our institution. Methods: Between 3/2015-8/2015, pts seen in the Adult Survivorship Program who had not previously received a TS/SCP were provided with one that included a list of survivorship research studies and care programscustomized to their diagnosis. Survivorship providers discussed the opportunities and recorded whether the pt was interested in relevant studies and placed referrals to study staff. Following the visit, we tracked study enrollment and surveyed pts about their experience. Results: 50/56 (89%) pts who participated in the pilot responded to the survey.Median age was 51 (range: 26-73); 78% were female; 54% were survivors of breast cancer; 42%, lymphoma; 2%, breast and lymphoma; 2%, colorectal cancer. Only 34% knew what a TS/SCP was before their visit; however 96% said having a TS/SCP would be helpful when visiting a primary care or other provider; 92% said the TS/SCP visit and document had or will help with knowledge of research opportunities and supportive care interventions. 90% responded that the study information they received was useful; 44% were interested in at least 1 study and would follow-up with a research coordinator. Of the 30 survivors eligible for ≥ 1 study, 5 have enrolled to date. Conclusions: This pilot program demonstrated that the systematic sharing of relevant clinical studies and supportive care programming as part of a TS/SCP visit is feasible and well-received by cancer survivors. Expansion of this novel program should help to enhance clinical research accrual for cancer survivors as well as ensure awareness of available supportive care interventions.
Detection of Twelve Nucleotides Instertion in the BCR-ABL Kinase Domain in an Imatinib-Resistant but Dasatinib-Sensitive Patient with Bi-Phenotypic Acute Leukemia.
Authors: Sandrine Hayette, Kaddour Chabane, Andrei Tchirkov, Marc G Berger, jean-Pierre Magaud, Franck E Nicolini, Olivier Tournilhac
Journal: Blood (2008)
Value of Synthetic Antigenic Determinants of Clavulanic Acid in Basophil Activation Test for Evaluating Immediate Reactions to Clavulanic Acid
Authors: Maria I. Montañez, Nekane Barbero, Tahia D. Fernandez, Angela Martin-Serrano, Gador Bogas, Adriana Ariza, Cristobalina Mayorga, Ezequiel Perez-Inestrosa, Maria J. Torres
Journal: Journal of Allergy and Clinical Immunology (2017)
P06.13 A low baseline blood neutrophil count and a high percentage of Treg among leucocytes are associated with an increased overall survival of recurrent high-grade glioma patients treated with Bevacizumab
Authors: V. Quillien, A. Carpentier, A. Gey, T. Avril, E. Tartour, F. Sejalon, B. Campillo-Gimenez, E. Vauleon
Journal: Neuro-Oncology (2016)
Recurrence and Mesh-Related Complications After Incisional Hernia Repair—Reply
Authors: Thue Bisgaard, Dunja Kokotovic, Frederik Helgstrand
Journal: JAMA (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Patients with carcinoma of unknown primary with isolated carcinomatosis on presentation: Clinicopathologic features and survival data.
Authors: H. R. Carlson, S. Karanth, M. A. Zarzour, R. Lenzi, M. N. Raber, G. R. Varadhachary
Journal: Journal of Clinical Oncology (2011)

4123 Background: Isolated or predominant carcinomatosis is not an uncommon presentation in patients with carcinoma of unknown primary (CUP). Primary peritoneal serous carcinoma (PPSC) is a well studied favorable CUP subset though data on non–PPSC is lacking and this group comprises of a large differential (gastric, colorectal, appendiceal, pancreatico-biliary and other cancer profiles). Information on the clinicopathologic characteristics and survival of these patients can help articulate a management strategy for these patients. Methods: Review of a M. D. Anderson Cancer Center CUP database from 2005 to 2010 has identified 64 patients in an ongoing study. Patients with predominant disease sites other than peritoneum/omentum were excluded. Data on demographics, imaging, detailed pathology, treatment, clinical course and survival was collected. Results: Median age of the patients is 56 years (range 31-86) and 38% are male. 13 (20%) women presented with typical PPSC. Immunohistochemistry (IHC) for all patients included a large range of markers – the most helpful in diagnosis were CK 7 (positive 46/72%), CK 20 (positive 33/51%), CDX-2 (positive 28, 44%), WT-1 (positive 9, 14%) and Calretinin (positive 2, 3%). 43 (67%) patients presented with ascites. First line treatments were grouped into: Colorectal regimens (FOLFOX/FOLFIRI based -30 pts/47%); Pancreaticobiliary regimens (Gemcitabine based - 5 pts/ 8%), taxane+platinum -21 pts/33%); other or no therapy -8 pts/12%. Median overall survival was 25 months (CI 20-30 months; OS not reached for PPSC and 22 months for non-PPSC patients). Conclusions: Uniform and limited IHC including CK 7/20; CDX-2, WT-1 and Calretinin are the most helpful first tier IHC in determining the cancer profile and choosing the best treatment strategy for isolated carcinomatosis CUP patients. Non-PPSC carcinomatosis is not an uncommon CUP presentation and these patients often are candidates for non taxane based therapies. Patients with a GI cancer (CDX-2 positive non-PPSC) IHC profile are good candidates for the colorectal armanentarium of drugs with survival of these patients similar to patients with metastatic colorectal cancer.
NIMG-06. DOES PERSONALIZING TUMOR TREATING FIELDS(TTFIELDS) WITH NOVOTAL IN GLIOBLASTOMA TREATMENT PLANNING MAKE A DIFFERENCE? INSIGHTS FROM ELECTRIC FIELD SIMULATION STUDIES
Authors: Aafia Chaudhry, Ze’ev Bomzon, Hadas Sara Hershkovich, Dario Garcia-Carracedo, Cornelia Wenger, Uri Weinberg, Yoram Palti
Journal: Neuro-Oncology (2016)

TTFields are an integral part of the glioblastoma clinical armamentarium and are delivered clinically via transducer arrays applied to the scalp. Array layout is planned using MRI coordinates for head size and tumor burden entered into the NovoTAL software. The system optimizes electric field (EF) intensity delivered to the tumor. TTFields distribute non-uniformly across the whole supratentorial brain and can reach therapeutic thresholds (>1 V/cm) across large areas. Complete proliferative arrest has been observed in glioma cell lines with applied field intensities of ~2.25V/cm. This study investigates the benefits of personalizing TTFields treatment using NovoTAL software compared with TTFields delivery using an unplanned, symmetric, midline array configuration. Treatment planning was performed for multiple tumors in distinct locations using post-contrast MRI sequences. EF simulations (realistic head model, ellipsoid tumors, orthogonal paired arrays (L-R and A-P), 200kHz) were performed for each tumor with 1) a NovoTAL personalized array layout, and 2) with a midline symmetric layout. EF intensity distributions were determined within the gross tumor volume (GTV) and 20mm peritumoral brain zone (PBZ) using both layouts. Personalized array layouts significantly increase the percentage of GTV receiving TTFields intensity >2.0 V/cm, delivered in an A-P direction (range 353%-6720%) across tested models. Additionally the total area of PBZ surrounding tumors and resection cavities receiving TTFields intensity >2.0 V/cm (A-P) is more than tripled using personalized array layouts (range 321%-690%). In the clinical setting, TTFields are delivered in 2 directions with a 1:1 duty cycle, hence optimizing field delivery in both directions is critical for improving patient outcomes. Treatment planning produces personalized array layouts that optimize the percentage of GTV and PBZ receiving highest therapeutic field intensities in both directions which is critical for maximizing therapeutic outcomes.
Recurrent Mutations in CCND3 Confer Clinical Resistance to FLT3 Inhibitors
Authors: Catherine C. Smith, Aaron D. Viny, Evan S. Massi, Cyriac Kandoth, Nicholas D. Socci, Henry Hsu, Brian West, Gideon Bollag, Barry S. Taylor, Ross L. Levine, Neil P. Shah
Journal: Blood (2015)
DOWN'S Syndrome Acute Lymphoblastic LEUKEMIA: A HIGHLY Heterogeneous DISEASE DRIVEN by an Aberrant CRLF2/JAK2 Cooperation – A REPORT FROM the Ibfm-STUDY GROUP.
Authors: Libi Hertzberg, Elena Vendramini, Ithamar Ganmore, Giovanni Cazzaniga, Maike Schmitz, Ruth Shiloh, Jane Chalker, Ilaria Iacobucci, Chen Shochat, Sharon Zeligson, Gunnar Cario, Martin Stanulla, Sabine Strehl, Lisa J Russel, Christine Harrison, Beat Bornhauser, Akinori Yoda, Gideon Rechavi, Dani Bercovich, Arndt Borkardt, Helena Kempski, Geertruy te Kronnie, Jean-Pierre Bourquin, Eytan Domany, Shai Izraeli
Journal: Blood (2009)
Validation of IDSA/ATS Algorithm for Duration of Pneumonia Therapy
Authors: Takahiro Mori, Makito Yaegashi, Shinya Hasegawa
Journal: JAMA Internal Medicine (2017)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
A traceless reversible polymeric colistin prodrug to combat multidrug-resistant (MDR) gram-negative bacteria
Authors: Chongyu Zhu, Elena K. Schneider, Jiping Wang, Kristian Kempe, Paul Wilson, Tony Velkov, Jian Li, Thomas P. Davis, Michael R. Whittaker, David M. Haddleton
Journal: Journal of Controlled Release (2017)

Colistin methanesulfonate (CMS) is the only prodrug of colistin available for clinical use for the treatment of infections caused by multidrug-resistant (MDR) Gram-negative bacteria. Owing to its slow and variable release, an alternative is urgently required to improve effectiveness. Herein we describe a PEGylated colistin prodrug whereby the PEG is attached via a cleavable linker (col-aaPEG) introducing an acetic acid terminated poly (ethylene glycol) methyl ether (aaPEG) onto the Thr residue of colistin. Due to the labile ester containing link, this prodrug is converted back into active colistin in vitro within 24h. Compared to CMS, it showed a similar or better antimicrobial performance against two MDR isolates of Pseudomonas aeruginosa and Acinetobacter baumannii through in vitro disk diffusion, broth dilution and time-kill studies. In a mouse infection model, col-aaPEG displayed acceptable bacterial killing against P. aeruginosa ATCC 27853 and no nephrotoxicity was found after systemic administration, suggesting it to be a potential alternative for CMS.
Inherited and Acquired Thrombophilic Abnormalities in Patients Aged &amp;lt;20 Years with Bcr-Abl Negative Chronic Myeloproliferative Disorders
Authors: Fiorina Giona, Angela Amendola, Giovanna Palumbo, Patrizia Pignoloni, Antonio Chistolini, Maria Luisa Moleti, Robert Foà, Maria Gabriella Mazzucconi
Journal: Blood (2008)
Peanut Introduction, Sensitization and Allergy Development in an Unselected Canadian Cohort
Authors: Elinor Simons, Diana L. Lefebvre, David Dai, Stuart E. Turvey, Padmaja Subbarao, Piushkumar Mandhane, Malcolm R. Sears, Allan B. Becker
Journal: Journal of Allergy and Clinical Immunology (2017)